Exactly.
So instead of just talking up the PRV, how about including more upfront info. Such as:
The RPDD is welcome recognition from the FDA. While a PRV would provide considerable value to the company, we have every intention to continue to rapidly advance RC220 in our lead indications. As such we expect that the award of a PRV unlikely due to seeking FDA approval in other indications before paediac AML.
Ann: FDA RPD Designation Granted for RC220 Bisantrene, page-30
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.77 |
Change
0.015(0.86%) |
Mkt cap ! $300.6M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.82 | $1.77 | $91.78K | 51.30K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 31147 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.80 | 8318 | 1 |
View Market Depth
| Last trade - 15.59pm 10/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |